# Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective

LOS ANGELES, CA - February 5, 2026 (NEWMEDIAWIRE) - Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well existing treatments work, rather than introducing entirely new drugs.

 * LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance
* Clinical programs are designed to enhance existing immunotherapies and chemotherapies rather than replace them
* Multiple active trials across ovarian clear cell cancer, colon cancer, and soft tissue sarcoma support a platform approach

 That strategy defines LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. Rather than developing standalone…

 Read More

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 Forward Looking Statements

 Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law 

---

[Original/Source Press Release](https://www.newmediawire.com/news/improving-the-odds-how-lixte-biotechnology-lixt-is-working-to-make-cancer-therapies-more-effective-7085267)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/lixte-biotechnology-targets-cancer-treatment-resistance-with-novel-enhancement-strategy/a242f25f9965b3eef0d6f4cf97483266) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/newmediawire/qrcode/262/5/noterToR.webp)